**To the Editor:** Melioidosis refers to infection caused by the facultative intracellular gram-negative bacterium *Burkholderia pseudomallei*. The clinical manifestations of melioidosis span a wide spectrum, from asymptomatic exposure or localized cutaneous infection to septic shock with multiorgan failure. Melioidosis usually occurs in residents of or travelers to disease-endemic areas in northern Australia and Southeast Asia; however, an increasing number of confirmed melioidosis cases are being reported from the Caribbean. We report a case of melioidosis acquired in Trinidad and Tobago.

In February 2014, a 17-year-old male student was admitted to a tertiary care hospital in Vancouver, British Columbia, Canada, with catecholaminergic polymorphic ventricular tachycardia and electrical storm. He had a 9-month history of dry cough that was unresponsive to multiple and prolonged courses of treatment for community-acquired pneumonia. During the 6 months before his admission, the patient had hemoptysis and radiologic evidence of pneumonia that were treated with courses of cephalosporins without resolution of symptoms. Bronchoscopy and culture of lavage samples had revealed infection with *Staphylococcus aureus* and an organism most closely related to *Actinomyces graevenitzii* *.*

The patient had no history indicative of risk factors for recurrent sinusitis or pneumonia (e.g., cystic fibrosis, chronic granulatomous disease, Job syndrome), and no risk factors for tuberculosis or infection with dimorphic fungi. He was up to date on his vaccinations and had no pets. He was born in Jamaica, had moved to Canada at age 4, and had not traveled anywhere other than Trinidad and Tobago, Canada, and England. He had traveled to visit family in Trinidad for 2 months during the rainy season in 2012, at which time he also visited Tobago.

On day 5 of hospital admission, the patient became febrile (39.6°C), and an infectious diseases specialist was consulted. Examination revealed that the patient was clinically stable but emaciated at 45 kg. His oxygen saturation while breathing room air was 98%. Physical examination, including cardiorespiratory examination, was unremarkable. Laboratory results showed a normal hemoglobin concentration of 133 g/L; elevated leukocyte count of 22.8 × 10^9^ cells/L; neutrophils 19.4 × 10^9^ cells/L; normal platelet count of 295 × 10^9^/L; and normal creatinine of 54 μmol/L. Test results for HIV-1 and blood cultures were negative. Computed tomography scan showed dilated bronchi and dense consolidation of the right and left lower lobes. Piperacillin/tazobactam was started for presumed hospital-acquired pneumonia.

The patient underwent diagnostic bronchoscopy with bronchoalveolar lavage. Gram staining of specimens showed occasional gram-negative bacilli, and aerobic cultures grew gram-negative bacilli. Further testing with the Vitek 2 (bioMérieux, Laval, Quebec, Canada) (96%) and RapID NF (Oxoid, Nepean, Ontario, Canada) (99.9%) systems identified *B. pseudomallei*, but matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Vitek MS, bioMérieux) did not. Phenotypic confirmation was performed at the provincial public health and reference laboratory. Antimicrobial drug susceptibility testing performed by broth microdilution according to Clinical and Laboratory Standards Institute recommendations ([@R1]) and by Etest (bioMérieux) showed susceptibility to amoxicillin/clavulanic acid, ceftazidime, imipenem, doxycycline, and trimethoprim/sulfamethoxazole. The patient's condition improved after 2 weeks of intravenous meropenem, and antimicrobial therapy was changed to oral trimethoprim/sulfamethoxazole.

The *B. pseudomallei* isolate was sent to the Public Health Agency of Canada's National Microbiology Laboratory for molecular typing. Query of 7 standard multilocus sequence typing loci (<http://bpseudomallei.mlst.net/>) identified the isolate as a novel multilocus sequence type. The sequence type (1,1,2,1,5,6,1) closely resembled that of *B. pseudomallei* previously isolated from the Caribbean ([@R2]).

Although melioidosis was first described in the Caribbean in 1947 ([@R3]), most case reports of the disease in the area are from the past 2 decades. This case report suggests progression of the range of melioidosis to include Trinidad and Tobago. A recent study documented the presence of *B. pseudomallei* in soil samples and high seroprevalence rates among contacts of persons with melioidosis in Puerto Rico ([@R4])*.* If examined, this pattern of regional melioidosis endemicity may also be found on other Caribbean islands.

Increased clinical awareness of and improved surveillance for *B. pseudomallei* infection may partly explain emergence. Nonetheless, underascertainment probably occurs in rural areas with limited access to advanced diagnostic support and in urban areas when *B. pseudomallei* infection is not suspected because of lack of travel to classic disease-endemic areas. Because *B. pseudomallei* is a Biosafety Level 3 agent, when infectious disease specialists consider melioidosis in their differential diagnoses, they should alert the microbiology laboratory to confirm species identification and ensure that staff use proper biosafety measures.

A total of 19 cases of melioidosis acquired in the Caribbean have been reported ([Table](#T1){ref-type="table"}). Nine of these were travel related, suggesting that melioidoisis may be emerging as a travel health issue. Travelers with known risk factors for melioidosis, such as diabetes mellitus and chronic lung disease, should be informed of their increased infection risk. Physicians should include *B. pseudomallei* in the differential diagnosis of travelers with pneumonia or sepsis who are returning from the Caribbean, particularly when they have a history of travel during the rainy season, soil-contaminated wounds, or known risk factors for melioidosis.

###### Published case reports of melioidosis from the Caribbean\*

  Ref.         Site of origin (year)           Age, y/sex   Type of exposure              Concurrent condition       Clinical manifestation                            Diagnostic method                              Treatment (duration)                                                                        Outcome
  ------------ ------------------------------- ------------ ----------------------------- -------------------------- ------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------- ----------
  ([@R3])      Panama (1947)                   31/M         Fall on buttock, TR           Polio, spinal meningitis   Buttock abscess                                   Abscess culture                                Sulfathiazole, sulfapyridine, streptomycin, penicillin                                      Survived
  ([@R5])      Panama (1948)                   25/F         UNK, TR                       None                       Retroperitoneal abscess, sepsis                   Abscess culture                                Penicillin, streptomycin                                                                    Died
  ([@R5])      Panama (1960)                   20/M         UNK                           None                       Acute septic arthritis                            Synovial fluid culture                         Chloramphenicol, novobiocin, sulfisoxazole                                                  Survived
  ([@R5])      Puerto Rico (1982)              62/F         UNK                           Diabetes, SLE, cirrhosis   Septic meningitis                                 Blood and CSF culture                          Penicillin, chloramphenicol, moxalactam, amikacin                                           Died
  ([@R5])      Mexico (1986)                   72/M         UNK                           None                       Pneumonia, splenic abscess                        Blood and sputum culture                       Cefoxitin, gentamicin                                                                       Died
  ([@R5])      Martinique (1995)               66/M         UNK, resident                 Diabetes                   Sepsis                                            Blood and urine culture                        IV ceftazidime, then oral TMP/SMX and doxycycline (2 mo)                                    Survived
  ([@R5])      Guadeloupe (1997)               4/M          UNK, TR                       None                       Pneumonia, pleural effusion, peritonitis          Pleural fluid culture                          IV ceftazidime and TMP/SMX(1 mo), then oral TMP/SMX (6 mo)                                  Survived
  ([@R5])      Puerto Rico (1997)              11/M         UNK, resident                 X-linked CGD               Mediastinitis, lymphadenitis                      Supraclavicular and hilar biopsy culture       Imipenem and doxycycline (6 weeks), oral cefixime and doxycycline (3 wk)                    Died†
  ([@R5])      El Salvador (2001)              UNK          UNK, TR                       UNK                        Cerebral abscess                                  UNK                                            UNK                                                                                         Survived
  ([@R4])      Puerto Rico (2003)              55/F         Flood water, resident         Diabetes                   Pneumonia, septic shock                           Blood and sputum culture                       Imipenum, amikacin, azithromycin                                                            Died
  ([@R6])      British Virgin Islands (2006)   17/M         UNK, resident                 CF                         Pneumonia                                         Sputum culture, PCR                            UNK                                                                                         Survived
  ([@R7])      Aruba (2009)                    7/F          UNK, TR                       CF                         Pneumonia                                         Oropharyngeal and induced sputum culture       Imipenem and ceftazidime (14 d), then inhaled meropenem (28 d) and long-term oral TMP/SMX   Survived
  ([@R4])      Puerto Rico (2009)              88/M         Ditch digging, resident       CAD, PVD                   Pneumonia                                         MLST                                           Doxycycline (20 wk), oral TMP/SMX                                                           Survived
  ([@R8])      Guadeloupe (2010)               15/F         UNK, TR                       Asthma, dengue fever       Adenopathy, tumefaction                           Tumefaction culture PCR                        IV ceftazidime (10 d), then oral TMP/SMX (12 wk)                                            Survived
  ([@R9])      Martinique (2010)               35/M         UNK, TR                       None                       Diarrhea, pneumonia                               Blood culture; PCR                             Imipenem, G-CSF                                                                             Died
  ([@R10])     Aruba (2012)                    46/F         Water exposure, TR            None                       Breast abscesses                                  Abscess culture                                Meropenem (14 d), then oral TMP/SMX (12 wk)                                                 Survived
  ([@R4])      Puerto Rico (2010)              38/M         Landscaping, resident         None                       Pneumonia, hepatitis, myocarditis, septic shock   Immunohistochemistry with polyclonal Ab; PCR   None                                                                                        Died
  ([@R4])      Puerto Rico (2012)              60/M         Agricultural work, resident   Diabetes                   Diabetic ketoacidosis                             Blood culture; MLST                            Amoxicillin/cloxacillin (10 d), then oral TMP/SMX (12 weeks)                                Survived
  This study   Trinidad and Tobago (2014)      17/M         Rainy season, TR              CPVT                       Chronic pneumonia                                 BAL culture; MLST                              Meropenem (2 weeks), then oral TMP/SMX (8 mo to date)                                       Survived

\*Ab, antibody; BAL, bronchoalveolar lavage; CAD, coronary artery disease; CGD, chronic granulomatous disease; CPVT, catecholaminergic polymorphic ventricular tachycardia; CSF, cerebrospinal fluid; G-CSF, granulocyte colony-stimulating factor; IV, intravenous; MLST, multilocus sequence typing; PVD, peripheral vascular disease; Ref., reference; SLE, systemic lupus erythematosus; TMP/SMX, trimethoprim/sulfamethoxazole; TR, travel related; UNK, unknown. †Cause of death unknown.
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